Abstract
Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 15-30 |
| Number of pages | 16 |
| Journal | Annals of Cancer Research and Therapy |
| Volume | 11 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - 2003 |
Keywords
- 5-FU
- Adenocarcinoma
- Bryostatin
- Cis-platin
- Docetaxel
- Drug toxicity
- G17DT
- Gastric cancer
- Irinotecan
- LV5FU2
- Marimastat
- Phase II and III trials
- Survival
- V325
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Pharmacology (medical)
